Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 101

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 8
Chunk 101
---
 sales.  Refer to discussion Sales Deductions and Related Accruals below. 

Sales Deductions and Related Accruals

We record accrued product returns and accrued product rebates as current liabilities in Accrued product returns and rebates, on our condensed consolidated balance sheets. We record sales discounts as a reduction against Accounts receivable, net on the unaudited condensed consolidated balance sheets. Both amounts are generally affected by changes in gross product sales, changes in the provision for net product sales deductions, and the timing of payments/credits.

27

The following table provides a summary of activity with respect to accrued product returns and rebates during the periods indicated (dollars in thousands): Accrued Product Returns and RebatesProductReturnsProductRebatesSales DiscountsTotalBalance at December 31, 2024$53,375 $115,330 $12,347 $181,052 Provision related to:Current year sales4,645 104,957 16,680 126,282 Prior year sales(6,988)253 99 (6,636)Total provision(2,343)105,210 16,779 119,646 Less: Actual payments/credits(1,107)(100,332)(15,362)(116,801)Balance at March 31, 2025$49,925 $120,208 $13,764 $183,897 

Accrued Product Returns and RebatesProductReturnsProductRebatesSales DiscountsTotalBalance at December 31, 2023$57,290 $96,984 $10,719 $164,993 Provision related to:Current year sales5,640 100,301 15,812 121,753 Prior year sales(1,403)668 38 (697)Total provision4,237 100,969 15,850 121,056 Less: Actual payments/credits(1,982)(90,272)(14,531)(106,785)Balance at March 31, 2024$59,545 $107,681 $12,038 $179,264 

Accrued Product Returns and Rebates

The accrued product returns balance decreased to $49.9 million as of March 31, 2025 from $59.5 million as of March 31, 2024. This decrease was primarily due to the